Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
MORGES, Switzerland--(BUSINESS WIRE)---- $INCY--Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC).
Hussman Strategic Advisors Inc. Has $2.67 Million Stock Position in Incyte Corporation $INCY
05:52am, Wednesday, 28'th Jan 2026
Hussman Strategic Advisors Inc. reduced its position in shares of Incyte Corporation (NASDAQ: INCY) by 50.0% in the undefined quarter, according to its most recent filing with the Securities and Excha
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
08:00am, Tuesday, 27'th Jan 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 8:00 a.m. ET on Tue
Here's Why Incyte (INCY) is a Strong Momentum Stock
10:51am, Monday, 26'th Jan 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Corporation $INCY Shares Purchased by Wealth Enhancement Advisory Services LLC
05:23am, Saturday, 24'th Jan 2026
Wealth Enhancement Advisory Services LLC raised its position in Incyte Corporation (NASDAQ: INCY) by 28.9% during the third quarter, according to its most recent filing with the SEC. The institutional
Why Incyte (INCY) is a Top Value Stock for the Long-Term
10:41am, Friday, 23'rd Jan 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Investors Should Know Before Buying Incyte
02:37am, Thursday, 22'nd Jan 2026
Incyte offers a compelling risk-adjusted return profile, outperforming healthcare benchmarks with robust growth and moderate volatility. INCY is successfully transitioning from Jakafi dependence to a
Donoghue Forlines LLC Invests $2.14 Million in Incyte Corporation $INCY
05:42am, Sunday, 18'th Jan 2026
Donoghue Forlines LLC bought a new position in Incyte Corporation (NASDAQ: INCY) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Excha
Incyte: Buy For The Turnaround, Stay For The Pipeline
01:34pm, Friday, 16'th Jan 2026
Incyte Corporation earns a Strong Buy rating, with recent execution driving a 56% stock rally and robust revenue growth. Jakafi sales rose 6.7% YoY in Q3 2025, defying terminal decline fears, while ex
Incyte's Pipeline Potential Signals Massive Upside For Investors
08:15am, Friday, 16'th Jan 2026
Incyte is a rare, profitable biotech with earnings doubling since 2021, driven by its core hematology franchise and rapidly expanding dermatology and oncology portfolios. INCY's non-Jakafi portfolio i
Steven Cress' Top 10 Stocks For 2026
11:00am, Thursday, 15'th Jan 2026
Micron Technology (MU) leads Steven Cress' Top 10 Stocks for 2026, driven by sector-leading growth, profitability, and a compelling valuation despite a 254% 1-year return. AI remains a central investm
Incyte CEO Bill Meury: Blood cancer therapy development is company's central identity
06:02pm, Tuesday, 13'th Jan 2026
Bill Meury, Incyte president and CEO, joins 'Fast Money' to talk potential M&A, its growth trajectory, its product pipeline, and more.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Tuesday, 13'th Jan 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:55pm, Monday, 12'th Jan 2026
Incyte Corporation (INCY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Will Incyte (INCY) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Monday, 12'th Jan 2026
Incyte (INCY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
